Quick Answer
Enliven Therapeutics, Inc. reported Total Assets of $476.17 million for fiscal year 2025.
Enliven Therapeutics, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $476.17M | +46.2% |
| 2024 | $325.76M | +19.8% |
| 2023 | $271.87M | +226.4% |
| 2022 | $83.30M | -11.1% |
| 2021 | $93.65M | +3.1% |
| 2020 | $90.84M | +172.8% |
| 2019 | $33.30M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $490.88M | +60.7% | -2.6% |
| June 30, 2025 | $503.89M | +54.1% | +66.5% |
| March 31, 2025 | $302.57M | -11.7% | -7.1% |
| December 31, 2024 | $325.76M | +19.8% | +6.7% |
| September 30, 2024 | $305.43M | +11.5% | -6.6% |
| June 30, 2024 | $327.04M | +13.4% | -4.6% |
| March 31, 2024 | $342.78M | +13.2% | +26.1% |
| December 31, 2023 | $271.87M | +226.4% | -0.8% |
- Enliven Therapeutics, Inc. showed an increase of +46.2% in Total Assets compared to the prior fiscal year.
- Over the 2019–2025 period, Enliven Therapeutics, Inc.’s total assets has grown by 1330.0% (from $33.30 million to $476.17 million).
- The most recent figure is from Enliven Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: